Evidence map›Paper›PMID 39066188›Full record

ArticleViruses2024

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era.

Guilherme Silva Julian, Júlia Spinardi, Melissa Diaz-Puentes, Diana Buitrago, Ida Caterina García, Moe H Kyaw

Erratum issuedAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Guilherme Silva JulianEvidence Generation Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil.ORCID 0000-0002-3487-2240
Júlia SpinardiVaccines Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil.
Melissa Diaz-PuentesReal World Insights (RWI), IQVIA, Bogotá 110110, Colombia.
Diana BuitragoReal World Insights (RWI), IQVIA, Bogotá 110110, Colombia.ORCID 0000-0001-9819-1279
Ida Caterina GarcíaReal World Insights (RWI), IQVIA, Ciudad de México C.P. 03810, Mexico.
Moe H KyawVaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc., Collegeville, PA 19426-3982, USA.ORCID 0000-0002-0258-6645

Funding

Pfizer Not applicable
6 · The paper itself

Abstract

We conducted a multicountry retrospective study using data from COVID-19 national surveillance databases to analyze clinical profiles, hospitalization rates, intensive care unit (ICU) admissions, utilization of ventilatory support, and mortality rates in five Latin American countries in the context of COVID-19 vaccination implementation. We analyzed the sociodemographic characteristics, comorbidities, clinical outcomes, and vaccination status of laboratory-confirmed COVID-19 cases from January 2021 to December 2022. We calculated the yearly and quarterly hospitalization rates per 1000 confirmed COVID-19 cases and ICU admissions, use of mechanical ventilators, and mortality rates per 1000 hospitalized cases, with their corresponding 95% confidence interval (CI) of 38,209,397 confirmed COVID-19 cases. Rates of hospitalization, ICU admission, ventilatory support, and death were higher among males than among females (30.6 vs. 25, 275.9 vs. 218.8, 156.4 vs. 118.6, and 388.4 vs. 363.1 per 1000, respectively); higher in 2021 than in 2022 (51.6 vs. 20.2, 471.4 vs. 75.5, 230.1 vs. 46.7, and 307.9 vs. 230.3 per 1000, respectively); and higher in the gt;50 age group (range: 4.3–16.3, 35.5–149.5, 20.1–83.2, and 315–462.9, per 1000) than the lt;50 age group (range: 0.8–5.7, 3.0–49.3, 2.1–39.3, and 7.8–217.7 per 1000). Hypertension and diabetes mellitus were the most common comorbidities in Mexico and Colombia. Prevention and treatment strategies for these case profiles could bring benefits from a public health perspective.

Indexed as

COVID-19COVID-19 VaccinesHospitalizationSARS-CoV-2AdolescentAdultAgedComorbidityFemaleHumansIntensive Care UnitsLatin AmericaMaleMiddle AgedRespiration, ArtificialRetrospective StudiesCOVID-19 VaccinescoronavirusCOVID-19fatal outcomeshospitalization rateLatin Americarisk factors

Identifiers

PMID39066188
PMCPMC11281361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.